Mass., May 2 /PRNewswire/ -- The BioSciences Group
of Fujitsu Computer Systems today announced a new
method that nearly doubles the efficiency of cell
transformation in difficult-to-transfect cell types,
based on the CELLINJECTOR(TM) automated microinjection
Michael J. McManus, vice
president of Business Development
for the BioSciences Group
of Fujitsu Computer Systems,
said, "We are pleased to announce
a method leveraging the expertise of Fujitsu in nanotechnology
and automation. The CELLINJECTOR vastly improves
the efficiency and throughput of cell injections,
easily performing thousands of successful injections
per day compared to hundreds done manually." He added, "Researchers
working on typically difficult-to-transfect cell
types including embryonic stem cells and adult stem
cells, among others, which have transfection efficiencies
as low as 15-20% using standard reagents could benefit
greatly from this technology. In a recent study using
the CELLINJECTOR technique, overall efficiency of
transformation of a mouse cell line was improved
to approximately 49%, nearly double the reported
averages for transfection for this cell type. This
workflow requires less technical proficiency among
users than existing manual microinjection systems,
but provides throughputs of up to 10 times that of
One advantage of the CELLINJECTOR-based workflow
is that other techniques such as electroporation
can cause substantial cell damage. Another and perhaps
even more problematic issue the new technique helps
circumvent is the fact that in all bulk transfection
approaches, it is impossible to differentiate between
cells which successfully admitted the vector but
failed to transcribe it from those cells which simply
did not allow entry of the vector. As transformed
cells are subsequently enriched for further study,
it is difficult to ascertain whether the phenotype
of the enriched, transfected population is the same
as the general population of cells.
Due to a combination of these limitations, the only
viable solution has been manual microinjection of
such cells -- a low-throughput, and prohibitively
time- and labor-intensive method. Automated microinjection
technologies such as CELLINJECTOR give researchers
direct determination of which cells actually received
construct, providing needed control over the process.
CELLINJECTOR consists of an integrated, computer-controlled
microscopic stage and microinjector system, a microfluidic
handling system and pressure control machinery. The
system enables automatic injection of suspended cells
and operator-assisted automatic injection of adherent
cells. CELLINJECTOR has a throughput several times
higher than conventional microinjection, injecting
up to 1,043 suspended cells in a single dish in 30
minutes and 500-600 adherent cells in an hour --
whereas manual injection methods can usually only
achieve hundreds of injections per day.
For more information, please download the CELLINJECTOR
whitepaper at us.fujitsu.com/biosciences.
About The BioSciences Group of Fujitsu Computer
The BioSciences Group of Fujitsu Computer Systems
Corporation is an established leader in creating
innovative and reliable solutions for experimental
scientists. BioSciences Group solutions enable researchers
to make in silico predictions about leads, targets,
and interactions, and to validate these hypotheses
experimentally. BioSciences Group offerings include
the CELLINJECTOR system for high-throughput, automated
cellular injection, and the CAChe(TM) suite of life
sciences predictive modeling and automated docking
tools, for drug discovery lead-generation. For more
information, please see: us.fujitsu.com/biosciences.
About Fujitsu Computer Systems Corporation
Headquartered in Sunnyvale, Calif., Fujitsu Computer
Systems is a wholly owned subsidiary of Fujitsu Limited
committed to the design, development and delivery
of advanced computer systems, application infrastructure
software products, and managed services for the business
enterprise. Through its TRIOLE strategy, the company
offers a complete line of scalable and reliable servers,
storage and middleware solutions, high- performance
mobile and client computers, as well as professional
services. Fujitsu Computer Systems has established
itself as a strategic solutions provider to the world's
leading organizations by offering technology innovation,
customer choice, exceptional product quality and
reliability, as well as outstanding customer service.
More information on Fujitsu Computer Systems is available
at http://us.fujitsu.com/computers .
Fujitsu is a leading provider of customer-focused
IT and communications solutions for the global marketplace.
Pace-setting device technologies, highly reliable
computing and communications products, and a worldwide
corps of systems and services experts uniquely position
Fujitsu to deliver comprehensive solutions that open
up infinite possibilities for its customers' success.
Headquartered in Tokyo, Fujitsu Limited reported
consolidated revenues of 4.7 trillion yen (US$44.5
billion) for the fiscal year ended March 31, 2005.
For more information, please see: www.fujitsu.com.
NOTE: Fujitsu, the Fujitsu logo, CAChe and CELLINJECTOR
are trademarks or registered trademarks of Fujitsu
Limited in the United States and other countries.
All other trademarks and product names are the property
of their respective owners.
The statements provided herein are for informational
purposes only and may be amended or altered by Fujitsu
Computer Systems Corporation without notice or liability.
Product description data represents Fujitsu design
objectives and is provided for comparative purposes;
actual results may vary based on a variety of factors.
Specifications are subject to change without notice.
Source: BioSciences Group of Fujitsu Computer Systems
CONTACT: Joshua Nathan, BioSciences Group of Fujitsu
+1-781-326-6330, or fax, +1-781-326-7179, or firstname.lastname@example.org ;
Fante of Aviator PR, +1-617-763-9887, or email@example.com
Web site: http://us.fujitsu.com/biosciences